This high-risk group includes patients with high-grade papillary stage Ta or T1 tumors and any patient with carcinoma in situ (CIS), and makes up 15–44% of patients with non-muscle-invasive ...

Aggressive Digital Papillary Adenocarcinoma (DPA ... For instance, a study utilizing in situ hybridization found that all examined DPA tumors tested positive for HPV42, while other sweat gland ...

75% of newly-diagnosed bladder cancer patients are assessed with Non-Muscle-Invasive Bladder Cancer (NMIBC), where: 90% have papillary ... the diseaseknown as Carcinoma In-Situ (CIS) (disease ...

with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer. According to the Centers for Disease Control and Prevention, about 57,000 ...

The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors.

ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the U.S. Food and Drug Administration (FDA) for patients with high-risk Bacillus Calmette-Guérin ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.